P2Y nucleotide receptors: Promise of therapeutic applications

Drug Discovery Today

Volumn 15, Issue 13-14, 2010, Pages 570-578

  Jacobson, Kenneth A ^a   Boeynaems, Jean Marie ^b,c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CANGRELOR; DENUFOSOL; DIQUAFOSOL; ELINOGREL; G PROTEIN COUPLED RECEPTOR; PURINERGIC P2Y RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TICAGRELOR; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

CARDIOVASCULAR DISEASE; CYSTIC FIBROSIS; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRY EYE; INFLAMMATORY DISEASE; NERVE DEGENERATION; REVIEW; THROMBOSIS;

ANIMALS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; LIGANDS; NEUROTRANSMITTER AGENTS; PURINERGIC P2 RECEPTOR AGONISTS; RECEPTORS, PURINERGIC P2;

EID: 77954308978     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.05.011     Document Type: Review

References (93)

1. Idzko M., et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat. Med. 2007, 13:913-919.
2. Elliott M.R., et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461:282-286.
3. Boeynaems J.M., et al. Overview of P2 receptors. Semin. Thromb. Hemost. 2005, 31:139-149.
4. Lazarowski E.R., et al. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol. Pharmacol. 2003, 64:785-795.
5. Abbracchio M.P., et al. International Union of Pharmacology LVIII. Update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 2006, 58:281-341.
6. 11 and SSF1 genes. J. Biol. Chem. 2001, 276:16561-16566.
7. Ivanov A.A., et al. Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling. J. Comput. Aided Mol. Des. 2006, 20:417-426.
8. 12 receptor. J. Pharmacol. Exp. Ther. 2009, 331:648-655.
9. 11 nucleotide receptor deduced from computational modelling and mutational analysis. Biochem. J. 2007, 405:277-286.
10. Erb L., et al. Site-directed mutagenesis of P2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. J. Biol. Chem. 1995, 270:4185-4188.
11. 14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol. Sci. 2003, 24:52-55.
12. Jankowski V., et al. Uridine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor. Nat. Med. 2005, 11:223-227.
13. Zamecnik P.C., et al. Analogues of diadenosine 5,5-P1,P4-tetraphosphate (Ap4A) as potential anti-platelet aggregation agents. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:2370-2373.
14. Shaver S.R., et al. Structure-activity relationships of dinucleotides: potent and selective agonists of P2Y receptors. Purinerg. Sig. 2005, 1:183-191.
15. Brunschweiger A., Müller C.E. P2 receptors activated by uracil nucleotides - an update. Curr. Med. Chem. 2006, 13:289-312.
16. 1 receptor of human platelets. J. Thromb. Haemost. 2006, 4:861-868.
17. 2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thio-UTP. J. Med. Chem. 2007, 50:1166-1176.
18. 6 nucleotide receptors activate NF-κB and increase survival of osteoclasts. J. Biol. Chem. 2005, 280:16909-16915.
19. 14 receptor. J. Med. Chem. 2007, 50:2030-2039.
20. 1 receptor antagonists as novel antithrombotic agents. Bioorg. Med. Chem. Lett. 2008, 18:3338-3343.
21. Kindon, N. et al. (1998) Novel compounds. WO/1998/054180.
22. 6 nucleotide receptors. Biochem. Pharmacol. 2004, 67:1763-1770.
23. 11 receptor antagonists with nanomolar potency. J. Med. Chem. 2005, 48:7040-7048.
24. 12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thromb. Haemost. 2007, 97:847-855.
25. 12 inhibitor. J. Thromb. Haemost. 2007, 5(Suppl. 2). P-T-292.
26. 13 receptor. Biochem. Pharmacol. 2005, 70:266-274.
27. (a) Belley, M. et al. (2009) Substituted 2-naphthoic acids as antagonists of GPR105 activity. WO 2009/070873A1. (b) Guay, D. et al. (2009) Substituted fused pyrimidines as antagonists of GPR105 activity. WO 2009/000087.
28. 1 receptors. J. Med. Chem. 1998, 41:183-190.
29. 1-receptor. Mol. Pharmacol. 1996, 50:1323-1329.
30. 1 receptor antagonists. J. Med. Chem. 2003, 46:4974-4987.
31. 1 receptors. Br. J. Pharmacol. 2006, 147:459-467.
32. 1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring. J. Med. Chem. 2007, 50:3229-3241.
33. 1/6 receptor agonists. Purinerg. Sig. 2008, 4:S18.
34. 1 receptor agonists. J. Med. Chem. 2002, 45:5384-5396.
35. Herpin, T.F. et al. (2005) Aminobenzazoles as P2Y1 receptors inhibitors. WO2005070920.
36. 1 receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18:6222-6226.
37. 2 agonists with enhanced stability over UTP. Bioorg. Med. Chem. Lett. 2007, 17:558-561.
38. 2 receptor antagonists. Bioorg. Med. Chem. 2009, 17:5071-5079.
39. 4 receptors. Biochem. Pharmacol. 2006, 71:540-549.
40. 12 receptor antagonist for the prevention of thrombosis. Bioorg. Med. Chem. Lett. 2007, 17:6013-6018.
41. Lazarowski E.R., et al. Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J. Biol. Chem. 2000, 275:31061-31068.
42. 6 receptor. J. Med. Chem. 2006, 49:5532-5543.
43. 6 receptors. J. Med. Chem. 2006, 49:7076-7087.
44. 6 receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. J. Med. Chem. 2005, 48:8108-8111.
45. 14 receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. J. Med. Chem. 2010, 53:471-480.
46. 11 receptor. Br. J. Pharmacol. 1999, 128:1199-1206.
47. 11 receptor antagonist with nanomolar potency. J. Med. Chem. 2005, 48:7040-7048.
48. 11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J. Pharmacol. Exp. Ther. 2010, 332:238-247.
49. Raju N.C., et al. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat. Clin. Pract. 2008, 5:766-780.
50. Harrington R.A., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 2009, 361:2318-2329.
51. 12 receptor oligomers and partitions them out of lipid rafts. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:11069-11074.
52. Tantry U.S., et al. AZD6140. Exp. Opin. Investig. Drugs 2007, 16:225-229.
53. Wallentin L., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2009, 361:1045-1057.
54. 12 antagonists for inhibition of platelet aggregation. J. Med. Chem. 2010, 53:2010-2037.
55. 12). Bioorg. Med. Chem. Lett. 2001, 11:1805-1808.
56. 12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog model. Thromb. Haemost. 2007, 97:847-855.
57. 12 inhibitors. Circulation 2010, 121:171-179.
58. Montalescot G., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009, 373:723-731.
59. Hagihara K., et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab. Dispos. 2009, 37:2145-2152.
60. Bhatt D.L., et al. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 2009, 361:2330-2341.
61. 12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr. Opin. Investig. Drugs 2010, 11:340-348.
62. Lazarowski E.R., Boucher R.C. Purinergic receptors in airway epithelia. Curr. Opin. Pharmacol. 2009, 9:262-267.
63. Nichols K.K., et al. Diquafosol tetrasodium: a novel dry eye therapy. Exp. Opin. Investig. Drugs 2004, 13:47-54.
64. Jin J., Kunapuli S.P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:8070-8074.
65. 1 receptor-null mice. J. Clin. Invest. 1999, 104:1731-1737.
66. 1-deficient mice. Nat. Med. 1999, 5:1199-1202.
67. 1 receptor, with strong antithrombotic activity in mice. J. Pharmacol. Exp. Ther. 2006, 316:556-563.
68. 4-null mice. Mol. Pharmacol. 2003, 63:777-783.
69. 4 receptors in the regulation of intestinal chloride secretion. Br. J. Pharmacol. 2005, 146:364-369.
70. Lacy B.E., Chey W.D. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Exp. Opin. Pharmacother. 2009, 10:143-152.
71. 1 receptors. Circulation 2008, 118:754-763.
72. 6 receptor in macrophages, endothelial cells, and vascular smooth muscle cells. Mol. Pharmacol. 2008, 74:777-784.
73. Guns P.J., et al. P2Y receptors and atherosclerosis in apolipoprotein E-deficient mice. Br. J. Pharmacol. 2010, 159:326-336.
74. Martinez L.O., et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003, 421:75-79.
75. 13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. Cell. Mol. Life Sci. 2005, 62:2508-2515.
76. 6 receptors on cardiomyocytes and release of UTP in man during myocardial infarction. Circ. Res. 2006, 98:970-976.
77. 12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J. 2008, 27:3104-3115.
78. Yitzhaki S., et al. Uridine-5'-triphosphate (UTP) reduces infarct size and improves rat heart function after myocardial infarct. Biochem. Pharmacol. 2006, 72:949-955.
79. 3 receptors. Science 2006, 314:1792-1795.
80. 2 nucleotide receptor mediates UTP-induced vascular cell adhesion molecule-1 expression in coronary artery endothelial cells. J. Biol. Chem. 2003, 278:24960-24965.
81. Marcet B., et al. Extracellular nucleotides regulate CCL20 release from human primary airway epithelial cells, monocytes and monocyte-derived dendritic cells. J. Cell. Physiol. 2007, 211:716-727.
82. 6 nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide. J. Biol. Chem. 2001, 276:26051-26056.
83. 11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. J. Immunol. 2001, 166:7172-7177.
84. la Sala A., et al. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J. Immunol. 2001, 166:1611-1617.
85. Atarashi K., et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008, 455:808-812.
86. Schnurr M., et al. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood 2005, 105:1582-1589.
87. 12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci. 2006, 9:1512-1519.
88. 6 receptors is a novel mediator of microglial phagocytosis. Nature 2007, 446:1091-1095.
89. 12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury. J. Neurosci. 2008, 28:4949-4956.
90. 12 receptor upregulation in activated microglia is a gateway of p38 signaling and neuropathic pain. J. Neurosci. 2008, 28:2892-2902.
91. Kauffenstein G., et al. NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. Cardiovasc. Res. 2010, 85:204-213.
92. 14 receptor. Mol. Pharmacol. 2009, 76:1341-1348.